Literature DB >> 29795767

Novel Nitric Oxide Donors of Phenylsulfonylfuroxan and 3-Benzyl Coumarin Derivatives as Potent Antitumor Agents.

Yalan Guo1, Yujie Wang2, Haihong Li1, Ke Wang1, Qi Wan1, Jia Li2, Yubo Zhou2, Ying Chen1.   

Abstract

In this work, five new hybrids of phenylsulfonylfuroxan merging 3-benzyl coumarin and their seco-B-ring derivatives 2-6 were designed and synthesized. Among them, compound 3 showed the most potent antiproliferation activities with IC50 values range from 0.5 to 143 nM against nine drug-sensitive and four drug-resistant cancer cell lines. Preliminary pharmacologic studies showed that these compounds displayed lower toxicities than that of lead compound 1. Compound 3 obviously induced the early apoptosis and hardly affected the cell cycle of A2780, which was significantly different from compound 1. Especially, it gave 559- and 294-fold selectivity antiproliferation activity in P-gp overexpressed drug-resistant cancer cell lines MCF-7/ADR and KB-V compared to their drug-sensitive ones MCF-7 and KB, implying that compounds 2-6 might have an extra mechanism of anti-MDR-cancer with P-gp overexpression.

Entities:  

Year:  2018        PMID: 29795767      PMCID: PMC5949836          DOI: 10.1021/acsmedchemlett.8b00125

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  31 in total

1.  Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT).

Authors:  Elaine M Gutierrez; Nicole A Seebacher; Laila Arzuman; Zaklina Kovacevic; Darius J R Lane; Vera Richardson; Angelica M Merlot; Hiu Lok; Danuta S Kalinowski; Sumit Sahni; Patric J Jansson; Des R Richardson
Journal:  Biochim Biophys Acta       Date:  2016-04-19

Review 2.  Turning the gun on cancer: Utilizing lysosomal P-glycoprotein as a new strategy to overcome multi-drug resistance.

Authors:  Nicole Seebacher; Darius J R Lane; Des R Richardson; Patric J Jansson
Journal:  Free Radic Biol Med       Date:  2016-05-03       Impact factor: 7.376

3.  Nitric oxide donor doxorubicins accumulate into Doxorubicin-resistant human colon cancer cells inducing cytotoxicity.

Authors:  Konstantin Chegaev; Chiara Riganti; Loretta Lazzarato; Barbara Rolando; Stefano Guglielmo; Ivana Campia; Roberta Fruttero; Amalia Bosia; Alberto Gasco
Journal:  ACS Med Chem Lett       Date:  2011-04-04       Impact factor: 4.345

4.  NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells.

Authors:  Satoshi Furuhashi; Hiroki Sugita; Hiroshi Takamori; Kei Horino; Osamu Nakahara; Hirohisa Okabe; Keisuke Miyake; Hiroshi Tanaka; Toru Beppu; Hideo Baba
Journal:  Int J Oncol       Date:  2011-10-24       Impact factor: 5.650

5.  Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein.

Authors:  Hiroki Sugita; Masao Kaneki; Satoshi Furuhashi; Masahiko Hirota; Hiroshi Takamori; Hideo Baba
Journal:  Mol Cancer Res       Date:  2010-07-27       Impact factor: 5.852

6.  Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance.

Authors:  Alexandra E Stacy; Duraippandi Palanimuthu; Paul V Bernhardt; Danuta S Kalinowski; Patric J Jansson; Des R Richardson
Journal:  J Med Chem       Date:  2016-08-30       Impact factor: 7.446

7.  Tumour maintenance is mediated by eNOS.

Authors:  Kian-Huat Lim; Brooke B Ancrile; David F Kashatus; Christopher M Counter
Journal:  Nature       Date:  2008-03-16       Impact factor: 49.962

8.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

Authors:  Jeffrey F Ohren; Huifen Chen; Alexander Pavlovsky; Christopher Whitehead; Erli Zhang; Peter Kuffa; Chunhong Yan; Patrick McConnell; Cindy Spessard; Craig Banotai; W Thomas Mueller; Amy Delaney; Charles Omer; Judith Sebolt-Leopold; David T Dudley; Iris K Leung; Cathlin Flamme; Joseph Warmus; Michael Kaufman; Stephen Barrett; Haile Tecle; Charles A Hasemann
Journal:  Nat Struct Mol Biol       Date:  2004-11-14       Impact factor: 15.369

Review 9.  Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.

Authors:  Gergely Szakács; Matthew D Hall; Michael M Gottesman; Ahcène Boumendjel; Remy Kachadourian; Brian J Day; Hélène Baubichon-Cortay; Attilio Di Pietro
Journal:  Chem Rev       Date:  2014-04-23       Impact factor: 60.622

10.  Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.

Authors:  Hongjuan Zhao; Shoucheng Ning; Jan Scicinski; Bryan Oronsky; Susan J Knox; Donna M Peehl
Journal:  Oncotarget       Date:  2015-12-22
View more
  4 in total

1.  Novel Nitric Oxide Donor Dinitroazetidine-Coumarin Hybrids as Potent Anti-Intrahepatic Cholangiocarcinoma Agents.

Authors:  Zhihui Yu; Mengru Li; Shiqi Guo; Weijie Wang; Feng Qu; Yulei Ma; Hongrui Liu; Ying Chen
Journal:  Molecules       Date:  2022-06-22       Impact factor: 4.927

2.  Synthesis and Antitumor Evaluation of Novel Hybrids of Phenylsulfonylfuroxan and Estradiol Derivatives.

Authors:  Qi Wan; Yan Deng; Yaoqing Huang; Zhihui Yu; Chunli Wang; Ke Wang; Jibin Dong; Ying Chen
Journal:  ChemistryOpen       Date:  2019-12-11       Impact factor: 2.911

Review 3.  Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms.

Authors:  Paras Famta; Saurabh Shah; Essha Chatterjee; Hoshiyar Singh; Biswajit Dey; Santosh Kumar Guru; Shashi Bala Singh; Saurabh Srivastava
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-09-06

4.  Possible involvement of L-arginine-nitric oxide pathway in the antidepressant activity of Auraptene in mice.

Authors:  Hossein Amini-Khoei; Shakiba Nasiri Boroujeni; Forough Maghsoudi; Mohammad Rahimi-Madiseh; Elham Bijad; Mohammadtaghi Moradi; Zahra Lorigooini
Journal:  Behav Brain Funct       Date:  2022-02-14       Impact factor: 3.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.